ChromaDex reports Q3 2023 net sales $19.5M (+14% YoY), positive adjusted EBITDA $0.5M

Niagen Bioscience, Inc.

2023-Q3 EPS reported -$0.07 revenue$62,374,000

Total net sales $19.5M (+14% YoY); Tru Niagen sales $17.4M (+19% YoY).
Gross margin 61.4% (up 160 bps); net loss $1.0M ($0.01 loss per share).
Adjusted EBITDA positive $0.5M, a $1.7M improvement from Q3 2022.
Cash $26.8M, no debt; positive operating cash flows for third consecutive quarter.
Launched Tru Niagen on iHerb in Aug; launched 1,000mg dosage in Oct; Zesty Paws partnership.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Niagen Bioscience, Inc. reported the third quarter of 2023 results: revenue $19.5 million, net income $1.0 million, EPS $(0.01) per share.

Period: the third quarter of 2023
Revenue: $19.5 million
Net income: $1.0 million
EPS: $(0.01) per share
Result: reported results

Exact text from the filing

ChromaDex Corporation Reports Third Quarter 2023 Financial Results Total net sales of $19.5 million, a gross margin of 61.4% and a net loss of $1.0 million while achieving a positive Adjusted EBITDA of $0.5 million and positive operating cash flows for the three months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037816

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.